This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CTRV ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV) 30 days 90 days 365 days Advanced Chart Get CTRV alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.53▼$3.5852-Week Range N/AVolume235,599 shsAverage Volume432,822 shsMarket Capitalization$34 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey. Read More Receive CTRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraVir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CTRV Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CTRV Stock Analysis - Frequently Asked Questions How were ContraVir Pharmaceuticals' earnings last quarter? ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) released its earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.68. When did ContraVir Pharmaceuticals' stock split? Shares of ContraVir Pharmaceuticals reverse split on Tuesday, May 29th 2018.The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of ContraVir Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Palatin Technologies (PTN) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings5/13/2016Today8/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CTRV CIK1583771 Webwww.contravir.com Phone732-902-4000FaxN/AEmployees14Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-4,810.77% Return on Assets-130.14% Debt Debt-to-Equity RatioN/A Current Ratio0.55 Quick Ratio0.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / BookN/AMiscellaneous Outstanding Shares800,000Free FloatN/AMarket Cap$34 thousand OptionableNot Optionable Beta1.16 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CTRV) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.